Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEDDI-R in Aggressive B-cell Lymphomas With Secondary CNS Involvement
NCT03964090Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2019
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in secondary central nervous system lymphoma (SCNSL), sponsored by National Cancer Institute. Started Jun 2019; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT03964090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964090.